Celgene Corp (CELG) 161.72 $CELG
Jim Cramer's 'Mad Money' Recap: Follow Your Own Investment Path
at The Street - Thu Jun 05, 7:08PM CDT
Investors need to be their own gurus and decide for themselves when it's time to buy and sell.
Final Glance: Biotechnology companies
AP - Thu Jun 05, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
3 Reasons Why Wall Street Hates Merrimack Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Jun 05, 12:43PM CDT
A rising short interest is often times a bad omen for a stock. Specifically, the high degree of risk involved in shorting tends to ensure that short-sellers have a clear cut investing thesis for why a particular stock is overvalued. Merrimack...
Celgene to Invest $25M in New Soon-Shiong Healthcare Venture
at The Street - Thu Jun 05, 12:42PM CDT
Celgene CELG is once again partnering with billionaire drug executive Patrick Soon-Shiong. Next Tuesday, Celgene will announce a $25 million investment in NantHealth, a healthcare technology company founded Soon-Shiong, TheStreet has learned.
Midday Glance: Biotechnology companies
AP - Thu Jun 05, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Watch For Today's Momo Momentum Stock: Celgene (CELG)
at The Street - Thu Jun 05, 11:52AM CDT
Trade-Ideas LLC identified Celgene (CELG) as a momo momentum candidate
Early Glance: Biotechnology companies
AP - Thu Jun 05, 9:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Stock Market News for June 05, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 9:06AM CDT
Benchmarks erased day’s initial losses and ended in the green after investors shrugged off dismal labor market data to focus on an encouraging services sector report
Jim Cramer's Top Stock Picks: PVH CELG REGN SKX
at The Street - Thu Jun 05, 5:00AM CDT
Cramer expects a second-half comeback for PVH while Skechers delivers solid performance.
After Yesterday's Rally of 2.13% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 04, 3:45PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $154.22 to a high of $159.23. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $155.71 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Celgene to Potentially Pullback after Yesterday's 2.13% Rise
Comtex SmarTrend(R) - Wed Jun 04, 3:44PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $154.22 to a high of $159.23. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $155.71 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Bargains in Biotech? Yes, They Exist
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Jun 03, 5:00PM CDT
Bargains in biotech? Isn't that an awfully good example of an oxymoron? Not according to a new study conducted by Richard Evans, a longtime Wall Street analyst. The study focuses on something that is inherently difficult: valuing a company's...
3 Reasons Celgene Is a Buy
Cory Renauer, The Motley Fool - Motley Fool - Mon Jun 02, 5:30PM CDT
Celgene was the subject of a recent downgrade from "overweight" to "neutral" by JPMorgan. Analysts didn't cite new concerns, but that won't stop media from speculating. In the face of uncertainty now is a great time to revisit the bull argument for...
Post-Hoc Analysis of Overall Survival in Phase III MPACT Study of Patients with Advanced Pancreatic Cancer Presented at ASCO 2014
Business Wire - Sun Jun 01, 8:00AM CDT
Celgene Corporation (NASDAQ: CELG) today announced updated Overall Survival (OS) results from a post-hoc analysis of its phase III MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer. A poster discussion of the analysis is scheduled for Sunday, June 1st at 11:30 am CT at the 50th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill.
Jim Cramer's 'Mad Money' Recap: Follow Your Own Investment Path
at The Street - Thu Jun 05, 7:08PM CDT
Investors need to be their own gurus and decide for themselves when it's time to buy and sell.
Final Glance: Biotechnology companies
AP - Thu Jun 05, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
3 Reasons Why Wall Street Hates Merrimack Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Jun 05, 12:43PM CDT
A rising short interest is often times a bad omen for a stock. Specifically, the high degree of risk involved in shorting tends to ensure that short-sellers have a clear cut investing thesis for why a particular stock is overvalued. Merrimack...
Celgene to Invest $25M in New Soon-Shiong Healthcare Venture
at The Street - Thu Jun 05, 12:42PM CDT
Celgene CELG is once again partnering with billionaire drug executive Patrick Soon-Shiong. Next Tuesday, Celgene will announce a $25 million investment in NantHealth, a healthcare technology company founded Soon-Shiong, TheStreet has learned.
Midday Glance: Biotechnology companies
AP - Thu Jun 05, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Watch For Today's Momo Momentum Stock: Celgene (CELG)
at The Street - Thu Jun 05, 11:52AM CDT
Trade-Ideas LLC identified Celgene (CELG) as a momo momentum candidate
Early Glance: Biotechnology companies
AP - Thu Jun 05, 9:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Stock Market News for June 05, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 9:06AM CDT
Benchmarks erased day’s initial losses and ended in the green after investors shrugged off dismal labor market data to focus on an encouraging services sector report
Jim Cramer's Top Stock Picks: PVH CELG REGN SKX
at The Street - Thu Jun 05, 5:00AM CDT
Cramer expects a second-half comeback for PVH while Skechers delivers solid performance.
After Yesterday's Rally of 2.13% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 04, 3:45PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $154.22 to a high of $159.23. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $155.71 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Celgene to Potentially Pullback after Yesterday's 2.13% Rise
Comtex SmarTrend(R) - Wed Jun 04, 3:44PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $154.22 to a high of $159.23. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $155.71 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Bargains in Biotech? Yes, They Exist
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Jun 03, 5:00PM CDT
Bargains in biotech? Isn't that an awfully good example of an oxymoron? Not according to a new study conducted by Richard Evans, a longtime Wall Street analyst. The study focuses on something that is inherently difficult: valuing a company's...
3 Reasons Celgene Is a Buy
Cory Renauer, The Motley Fool - Motley Fool - Mon Jun 02, 5:30PM CDT
Celgene was the subject of a recent downgrade from "overweight" to "neutral" by JPMorgan. Analysts didn't cite new concerns, but that won't stop media from speculating. In the face of uncertainty now is a great time to revisit the bull argument for...
Post-Hoc Analysis of Overall Survival in Phase III MPACT Study of Patients with Advanced Pancreatic Cancer Presented at ASCO 2014
Business Wire - Sun Jun 01, 8:00AM CDT
Celgene Corporation (NASDAQ: CELG) today announced updated Overall Survival (OS) results from a post-hoc analysis of its phase III MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer. A poster discussion of the analysis is scheduled for Sunday, June 1st at 11:30 am CT at the 50th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill.
